AI-generated summary
The authors report a randomized, double-blind, sham-controlled trial of an intraoral LED photobiomodulation device in 85 head and neck cancer patients receiving radiotherapy. They found no device-related adverse events and lower rates of severe oral mucositis with the device in the intent-to-treat analysis, though the evidence was modest and the trial was small.
- Participants
- 85
- Who or what was studied
- Patients with head and neck cancer undergoing high-dose intensity modulated radiation therapy, with or without concurrent chemotherapy, enrolled across 12 US sites
- Limits stated in the abstract
- The abstract reports a modest sample of 85 participants and a per-protocol analysis with several secondary outcomes, and does not state the wavelengths used by the device.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Sham, Oral mucositis, Light-emitting diode, Dose, Trial registration, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.